Browse Category: Cancer Treatment

Erick Lefkofsky Enhances Cancer Treatment

Lefkofsky is one of the most popular experts in health technology, in United States. He is a co-founder and CEO of Tempus, a health technology firm headquartered in Chicago. Erick has made significant steps in building technology solutions aimed at modernizing the treatment of cancer. Tempus has made it easy for cancer health-providers to improve their services. It has also brought a lot of benefits to cancer-patients.

Accurate analysis of clinical and molecular data

Lefkofsky and his team have made it possible for cancer healthcare-professionals to accurately analyze and match a patient’s clinical and molecular data. This technology-platform has enabled doctors to make real time decisions and implement effective treatment to the patients. As opposed to the traditional data management techniques, the solution makes it easy for experts to collect data, analyze and generate reports useful in decision making process.

The Tempus staff is focused on helping cancer-patients. Their software has been seen to bring significant benefits in the health-sector. It is particularly projected to bring important changes in cancer-care.

Erick Lefkofsky

Erick Lefkofsky is a name that many medics in the United States are familiar with. This is because of his hard work and great contribution to the health sector. The now famous American entrepreneur began from a humble background. Erick was born in the year 1969 in Detroit, Michigan in United States. In 1991, he graduated with high honors from the University of Michigan. Two years later, he received his Juris doctor degree from the University of Michigan Law School.

The 49 year old is currently the CEO of Tempus, one of the most-reputable technology firms in the US. Lefkofsky co-founded Tempus, Uptake Technologies and Echo Global Logistics just to mention a few. Erick has served in several senior-management positions through his career.

Eric Paul Lefkofsky Is a Community Person

Unlike other entrepreneurs, he is not only focused on wealth generation. Erick holds the interest of the community at heart. His love for people has been echoed by his staff and the local community. Erick and his wife established Lefkofsky Family Foundation, a charity organization in 2016.

Respecting Erick Lefkofsky: lefkofskyfoundation.com/about-eric-lefkofsky/

Clay Siegall develops niche market for Seattle Genetics

Despite dramatic improvements in the survival rates of almost all types of cancer between the turn of the 20th century in the mid-twentieth century, many types of cancer have not seen dramatic improvements since then. This is largely due to the fact that most of the major breakthroughs in cancer treatment happened between the 1930s and the 1960s. Today, that is beginning to change. However, prior to the year 2000, the three main pillars of cancer treatment, surgery, radiation and chemotherapy, were the same ones that had existed since the 1930s and 40s.

It was with this in mind that a senior researcher at Bristol-Myers Squibb named Clay Siegall decided to branch out on his own, concentrating on developing novel treatments for some of the cancer types that had not seen significant mortality improvements over the preceding 50 years. By 1998, the year in which Dr. Siegall founded Seattle Genetics, he had been working as a top cancer researcher for more than 15 years. He had decided in college that he wanted to pursue a career in cancer research when one of his family members got sick with cancer. Although they eventually pulled through, they nearly died at one point, not due to the disease itself but due to the development of severe anemia secondary to the chemotherapeutic regime that was necessary to treat it. This made Dr. Siegall realize that there must be a better way to go about fighting this horrible disease.

Upon founding Seattle Genetics, Dr. Siegall decided that he would not follow the same strategies as other pharmaceutical companies. After all, they had huge economies of scale and already had large portions of their market completely cornered. Instead, Dr. Siegall decided to go after areas which had been largely neglected and in which little progress had been made over the prior decades. One such area was the disease called non-Hodgkins lymphoma.

Dr. Siegall began developing a drug called ADCetris, an antibody drug conjugate that was specifically designed for the treatment of non-Hodgkin’s lymphoma. It eventually became the first FDA-approved antibody drug conjugate, saving the lives of thousands of patients and propelling Seattle Genetics into the realm of major pharmaceutical players.